ABCL stock forecast, quote, news & analysis
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need... Show more
Why AbCellera Biologics (ABCL) Stock Is Up +131% in the Last 30 Days
Key Takeaways
- ABCL shares have climbed roughly 131% over the past 30 days, rising from about $5.29 to $12.24 as of the most recent close.
- The surge was driven primarily by positive Phase 2 data for ABCL635, the company’s investigational non-hormonal antibody for menopausal hot flashes.
- Analysts raised price targets after the readout, and the stock touched a 52-week high of $12.50 in late August.
- The broader three-month trend is also strongly positive, with shares up about 114% over the last quarter.
- Key risks include ongoing net losses, lumpy partnership revenue, and the need for ABCL635 to deliver in late-stage trials.
AbCellera Biologics (ABCL) Company Overview and Market Position
AbCellera Biologics Inc. is a clinical-stage biotechnology company headquartered in Vancouver, Canada. The company operates an artificial intelligence-driven antibody discovery platform that searches natural immune systems to identify therapeutic antibodies, and it works with partners across the pharmaceutical industry to accelerate drug discovery. Over time, AbCellera has evolved from a discovery-services provider into a clinical-stage firm with its own internal pipeline, while maintaining research collaborations and licensing arrangements with partners such as Eli Lilly, Jazz Pharmaceuticals (JAZZ), and Vertex Pharmaceuticals (VRTX). Investors follow the stock closely because of its differentiated platform, its transition toward internal drug development, and a pipeline that includes ABCL635 for vasomotor symptoms associated with menopause and ABCL575 for immunology indications.
AbCellera Biologics (ABCL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ABCL has delivered a sharp upward move, advancing from roughly $5.29 to $12.24, a gain of about 131%. The stock initially traded in a relatively narrow range through late July before accelerating sharply in August after the company announced clinical data for its lead program. The rally pushed shares to a 52-week high of $12.50 on August 25, 2026, well above the 52-week low of $2.75 set earlier in the year.
The last quarter tells a similar story over a longer horizon. Three months ago, ABCL traded near $5.73, meaning the stock has gained approximately 114% over the quarter. This extended advance reflects a combination of strengthening clinical momentum, a series of new partnership announcements, and a broader shift in investor sentiment toward the company’s internal pipeline rather than only its discovery-services business.
What Drove ABCL Stock Price in the Last 30 Days
The dominant catalyst behind the 30-day move was the August 10, 2026 announcement of positive top-line results from the Phase 2 portion of a Phase 1/2 trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody being developed as a non-hormonal, long-acting subcutaneous treatment for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. The randomized, double-blind, placebo-controlled study enrolled 92 postmenopausal women. After a single 600 mg dose, patients receiving ABCL635 experienced an 83% reduction in hot flash frequency at week four compared with a 33% reduction for placebo, along with a 58% versus 12% reduction in symptom severity. The treatment was well tolerated, with no serious adverse events or discontinuations, and also showed improvements in sleep and patient-reported outcomes.
The readout triggered a single-day gain of more than 30% and drew meaningful analyst attention. Following the results, multiple firms raised their price targets on the stock, reflecting increased confidence in ABCL635’s commercial potential in the multibillion-dollar menopause market. The company subsequently announced a roughly $200 million public offering in mid-August to fund the advancement of ABCL635 and its broader pipeline. These developments occurred against a backdrop of earlier strategic momentum, including a June 2026 collaboration with Jazz Pharmaceuticals and a July 2026 collaboration with Vertex Pharmaceuticals, which together reinforced the company’s partnering strategy.
What Drove ABCL Stock Performance Over the Last Quarter
Over the last three months, ABCL’s roughly 114% advance has been shaped by a broader repositioning of the company’s narrative. Investors have increasingly valued AbCellera for its internal drug pipeline rather than its legacy discovery-services revenue, which has been volatile and lumpy from quarter to quarter. The company’s second-quarter 2026 results, reported in early August, showed total revenue of about $4.1 million, down sharply year over year, and a net loss of roughly $55.4 million, while cash, cash equivalents, and marketable securities stood at approximately $540.1 million. Despite the widening losses, the market focused on the company’s strong balance sheet, its clinical progress, and its stream of new partnerships. The positive ABCL635 data in August served as the decisive catalyst that compressed months of clinical anticipation into a rapid repricing of the shares.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights a curated selection of AI-driven trading bots that are actively trading across thousands of tickers. While Tickeron offers hundreds of these automated bots, only the top-performing and most relevant ones appear in this section, helping traders quickly identify strategies that are currently standing out. The bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term momentum approaches to longer-term trend-following models, so users can compare options based on their own objectives and risk tolerance. For traders looking to complement their own research with data-driven automation, reviewing the Trending AI Robots section can be a practical starting point.
ABCL Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring ABCL should pay close attention to several forward-looking factors. The most important near-term item is the additional 12-week data from the ABCL635 Phase 2 study, which the company has indicated is expected later in the year and should provide a fuller picture of durability and safety. The company’s plans to advance ABCL635 toward a Phase 3 program, including trial design and regulatory interactions, will also shape the investment case. Separately, initial results from the Phase 1 study of ABCL575 for immunology indications are expected in the fourth quarter of 2026. Broader considerations include the pace of cash burn, the ability to convert partnerships into milestone and royalty revenue, and the company’s next quarterly earnings report, currently estimated for early November 2026. As with any clinical-stage biotechnology company, trial outcomes and regulatory decisions remain significant sources of risk and volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ABCL in downward trend: price expected to drop as it breaks its higher Bollinger Band on August 06, 2026
ABCL broke above its upper Bollinger Band on August 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In of the 40 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ABCL moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where ABCL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on September 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABCL as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
ABCL moved above its 50-day moving average on August 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABCL crossed bullishly above the 50-day moving average on August 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 155 cases where ABCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.108) is normal, around the industry mean (20.583). P/E Ratio (0.000) is within average values for comparable stocks, (27.923). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.559). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (51.813) is also within normal values, averaging (443.835).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology